Close monitoring and early intervention : management principles for cystic fibrosis in Denmark
© 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology..
Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica - 132(2024), 4 vom: 25. März, Seite 223-235 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qvist, Tavs [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Infective Agents |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/apm.13375 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367578204 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367578204 | ||
| 003 | DE-627 | ||
| 005 | 20240314234945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apm.13375 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM367578204 | ||
| 035 | |a (NLM)38267398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qvist, Tavs |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Close monitoring and early intervention |b management principles for cystic fibrosis in Denmark |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology. | ||
| 520 | |a Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Standard of care | |
| 650 | 4 | |a benchmarking | |
| 650 | 4 | |a clinical practice | |
| 650 | 4 | |a guideline | |
| 650 | 4 | |a outcome | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 700 | 1 | |a Nielsen, Bibi Uhre |e verfasserin |4 aut | |
| 700 | 1 | |a Olesen, Hanne Vebert |e verfasserin |4 aut | |
| 700 | 1 | |a Mathiesen, Inger Hee Mabuza |e verfasserin |4 aut | |
| 700 | 1 | |a Faurholt-Jepsen, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Katzenstein, Terese L |e verfasserin |4 aut | |
| 700 | 1 | |a Helweg-Larsen, Jannik |e verfasserin |4 aut | |
| 700 | 1 | |a Rönsholt, Frederikke |e verfasserin |4 aut | |
| 700 | 1 | |a Jeppesen, Majbritt |e verfasserin |4 aut | |
| 700 | 1 | |a Olsen, Mette Frahm |e verfasserin |4 aut | |
| 700 | 1 | |a Buchvald, Frederik Fouirnaies |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Kim Gjerum |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen-Fangel, Søren |e verfasserin |4 aut | |
| 700 | 1 | |a Pressler, Tania |e verfasserin |4 aut | |
| 700 | 1 | |a Skov, Marianne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t APMIS : acta pathologica, microbiologica, et immunologica Scandinavica |d 1989 |g 132(2024), 4 vom: 25. März, Seite 223-235 |w (DE-627)NLM012602744 |x 1600-0463 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2024 |g number:4 |g day:25 |g month:03 |g pages:223-235 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apm.13375 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2024 |e 4 |b 25 |c 03 |h 223-235 | ||